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Phosphodiesterase-4D Knock-
down in the Prefrontal Cortex 
Alleviates Chronic Unpredictable 
Stress-Induced Depressive-Like 
Behaviors and Memory Deficits in 
Mice
Zhen-Zhen Wang1,2, Wei-Xing Yang1,3, Yi Zhang4, Nan Zhao1, You-Zhi Zhang1, Yan-Qin Liu1, 
Ying Xu6, Steven P. Wilson5, James M. O'Donnell6, Han-Ting Zhang7 & Yun-Feng Li1
Phosphodiesterase 4 (PDE4) has four isoforms (PDE4A-D) with at least 25 splice variants. PDE4 
subtype nonselective inhibitors produce potent antidepressant-like and cognition-enhancing 
effects via increased intracellular cyclic AMP (cAMP) signaling in the brain. Our previous data have 
demonstrated that long-form PDE4Ds appear to be involved in these pharmacological properties 
of PDE4 inhibitors in the normal animals. However, it is not clear whether long-form PDE4Ds are 
critical for the behaviors and related cellular signaling/neuronal plasticity/neuroendocrine alterations 
in the depressed animals. In the present study, animals exposed to the chronic unpredictable stress 
(CUS), a rodent model of depression, exhibited elevated corticosterone, depressive-like behavior, 
memory deficits, accompanied with decreased cAMP-PKA-CREB and cAMP-ERK1/2-CREB signaling 
and neuroplasticity. These alterations induced by CUS were reversed by RNA interference (RNAi)-
mediated prefrontal cortex long-form PDE4Ds (especially PDE4D4 and PDE4D5) knock-down, similar 
to the effects of the PDE4 subtype nonselective inhibitor rolipram. Furthermore, these effects of 
RNAi were not enhanced by rolipram. These data indicate a predominant role of long-form PDE4Ds 
in the pharmacotherapies of PDE4 inhibitors for depression and concomitant memory deficits. 
Long-form PDE4Ds, especially PDE4D4 and PDE4D5, appear to be the promising targets for the 
development of antidepressants with high therapeutic indices.
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Long-term exposure to unpredictable life stressors is a major precipitating factor in the development 
of depression in humans1. In addition, depression is generally accompanied by memory deficits which 
are critical determinants of functional outcome in this population2. Chronic unpredictable stress (CUS) 
is currently recognized as a valid model of depression and is typically used in rodents to resemble the 
human depressive-like state3 and concomitant memory deficits4.
Phosphodiesterase-4 (PDE4) inhibitors such as rolipram produce antidepressant-like5,6 and 
cognition-enhancing effects7–10 via cAMP signaling6,11. The cAMP signaling cascade is important in the 
mediation of neuroplasticity12, which is the neurochemical substrate of antidepressant efficacy13 and cog-
nitive functions14. Although rolipram produces preclinical and clinical antidepressant efficacy, its thera-
peutic utility is limited by problematic side effects such as severe nausea and emesis15.
The PDE4 family is encoded by four genes (PDE4A-D) and multiple variants16,17. The PDE4D isoform 
has attracted considerable attention given that it is potential therapeutic target in the treatment of depres-
sion18–20 and memory deficits11,21–23. Unfortunately, deficiency of PDE4D also causes the emetic-like 
response11,24. This is consistent with the enrichment of PDE4D in the area postrema and nucleus tractus 
solitarius25, two structures that are known to be involved in the emetic response26. Excitingly, selective 
PDE4D allosteric modulators22 and PDE4D selective inhibitor21 incompletely inhibit PDE4 activity and 
enhance memory but have reduced potential to cause emesis.
We have previously indicated long-form PDE4D variants, especially PDE4D4 and PDE4D5, may play 
important roles in the mediation of antidepressant-like and cognition-enhancing effects but appear not 
to cause emesis in normal mice11,20. However, there is no evidence of long-form PDE4Ds on the altera-
tions in neuroendocrine, impaired neuronal plasticity, cellular and behavioral disturbances in response to 
CUS. The gap between this promising pharmacotherapeutic target and the pathophysiology of depression 
hampers the development of PDE4D variant-selective inhibitors into novel antidepressants.
Hence, the present study was designed to investigate the roles of long-form PDE4Ds in 
antidepressant-like and cognition-enhancing effects employing the CUS model in mice. The RNA inter-
ference (RNAi) technique was applied to the long-form PDE4Ds knock-down. We hypothesized that 
long-form PDE4Ds played a predominant role in the pharmacotherapies of PDE4 inhibitors for depres-
sion and concomitant memory deficits.
Results
Effects of 4DmiR microinfusion on CUS-induced changes in expression of long-form PDE4D 
variants. The lentivirus-mediated microinfusion in vivo was traced by the high and specific expression 
of EGFP (Fig.  1a). The expressions of PDE4D4 and PDE4D5 in chronically stressed mice were signif-
icantly increased [F(4,14) = 18.48, P < 0.05 and F(4,14) = 6.49, P < 0.05, respectively], compared with 
the control. 4DmiR treatment reversed these increases and significantly down-regulated the levels of 
PDE4D4 (P < 0.001) and PDE4D5 (P < 0.01), similar to the effects of rolipram administration (P < 0.001 
for PDE4D4 and P < 0.05 for PDE4D5). In addition, rolipram did not alter the effects of 4DmiR on the 
expressions of PDE4D4 and PDE4D5. The expression of PDE4D3 was not substantially changed by CUS 
exposure and 4DmiR treatment (Fig. 1b,c).
Effects of 4DmiR on CUS-induced changes in neuroendocrine and physical state. Following 
the CUS regimen, the serum corticosterone level in chronically stressed mice was higher than that in 
non-stressed mice [Fig.  2a; F(4, 22) = 8.005, P < 0.001]. 4DmiR treatment attenuated this alteration 
and significantly reduced corticosterone concentrations, compared with vehicle/NC-treated CUS mice 
(P < 0.01), similar to the effect of rolipram administration (P < 0.01). In addition, the effect of 4DmiR 
on the serum corticosterone level was not changed in the presence of rolipram.
CUS led to a significant deterioration of coat state from week 2 to week 4 as demonstrated by an 
increased coat state score [Fig. 2b; week 2: F(4, 40) = 2.893, P < 0.05; week 3: F(4, 40) = 8.344, P < 0.001; 
week 4: F(4, 40) = 21.33, P < 0.001]. 4DmiR (P < 0.01) or rolipram (P < 0.05) significantly prevented this 
degradation from the third week. And the effect of 4DmiR plus rolipram on coat state was observed at 
the fourth week (P < 0.05).
Body weight was measured before the onset of the CUS regimen and then weekly until the end of the 
CUS procedure. CUS mice showed a reduction of the body weight gain only at the second week [Fig. 2c; 
F(4, 40) = 5.063, P < 0.05)]. While rolipram alone or in combination with 4DmiR significantly disrupted 
the normal gain in body weight as compared with the control starting from the second week [week 2: 
F(4, 40) = 5.063, P < 0.01 for rolipram alone or in combination with 4DmiR; week 3: F(4, 40) = 7.985, 
P < 0.001 for rolipram alone, P < 0.05 for rolipram plus 4DmiR; week 4: F(4, 40) = 4.892, P < 0.05 for 
rolipram alone]. 4DmiR alone did not affect the body weight gain.
Effects of 4DmiR on CUS-induced depressive-like behaviors. Anhedonia which is defined 
by decreased sucrose preference is the core symptom of depression and is suitable for monitor the 
depressive-like state in rodents27. To define the dynamics of the CUS response, the sucrose preference 
of each mouse was evaluated weekly. Initially, all groups of mice had a similar sucrose preference in 
baseline conditions (before stress, Fig. 3a). While a significant drop of sucrose preference was observed 
after 4-week stress procedure [Fig. 3b; F(4, 40) = 4.080, P < 0.001]. 4DmiR treatment reversed this alter-
ation and significantly increased the sucrose preference compared with vehicle/NC-treated CUS mice 
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(P < 0.05), similar to the effect of rolipram administration (P < 0.05). In addition, the effect of 4DmiR 
on the sucrose preference was not changed in the presence of rolipram.
Assessing the behaviors of mice, we found a 64.1% increase of the immobility time in the FST [Fig. 3c; 
F(4, 40) = 3.880, P < 0.01] and a 85.9% increase of the latency to feed in the NSF test [Fig.  3d; F(4, 
40) = 2.839, P < 0.01] after the CUS procedure. 4DmiR treatment attenuated these alterations and sig-
nificantly reduced the immobility time in the FST (P < 0.05) and the latency to feed in the NSF test 
(P < 0.05). A similar tendency was observed in mice treated with rolipram (FST: P < 0.01; NSF: P < 0.05). 
In addition, the effects of 4DmiR on the immobility time and the latency to feed were not changed in 
the presence of rolipram.
Effects of 4DmiR on CUS-induced memory deficits. In the NOR test, mice exposed to stressors 
showed impairment in recognition memory revealed by a significant decrease in the recognition index in 
comparison with the controls [Fig. 4a; F(4, 40) = 5.502, P < 0.05] and this effect was reversed by 4DmiR 
treatment (P < 0.01). Similar result was also observed in mice treated with rolipram (P < 0.05) and the 
effect of 4DmiR on the recognition index was not changed in the presence of rolipram.
In the MWM task, during the 3-day acquisition training, all the mice displayed progressive decreases 
in the latency to find the submerged platform over training trials. Mice exposed to CUS had longer 
latencies to reach the platform than the controls [Fig.  4b; Trial 2: F(4, 40) = 2.147, P < 0.05; Trial 5: 
Figure 1. Effects of 4DmiR on CUS-induced changes in the expression of long-form PDE4D variants. 
(a) Microinjection sites and high, specific expressions of EGFP (green) in the prefrontal cortices observed 
under fluorescence microscopy. Scale bars = 500 μ m. (b) Representative cropped immunoblots of long-form 
PDE4D variants (full-length blots are presented in Supplementary Figure S1). The prefrontal cortical tissues 
of 3 mm in diameter around the injection site were punched out for western blot analysis. All gels were run 
under the same experimental conditions and blots were processed in parallel. The boundary between the 
gels was delineated by a black line. (c) The histogram represents semi-quantitative results of western blot 
analysis. The values of densitometric analysis were normalized by the level of β-actin. Values shown are 
means ± SEM; n = 3-4; *P < 0.05, compared with non-stressed control (NC + Veh); #P < 0.05, ##P < 0.01, 
###P < 0.001 compared with CUS (NC + Veh).
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F(4, 40) = 1.303, P < 0.05; Trial 10: F(4, 40) = 1.887, P < 0.05]. And the stressed mice treated with 
4DmiR alone or plus rolipram spent less time to find the submerged platform [Trial 10: F(4, 40) = 1.887, 
P < 0.05; Trial 11: F(4, 40) = 1.897, P < 0.05; Trial 12: F(4, 40) = 1.281, P < 0.05]. In the probe trial test 
performed 24 h after the last acquisition trial, stressed mice displayed robust decreases in durations 
[F(4, 40) = 2.595; P < 0.05] but not entries [F(4, 40) = 2.347; P > 0.05] in the target quadrant, as shown 
in Fig.  4c,d. 4DmiR treatment reversed this alteration and significantly increased the durations and 
entries in the target quadrant compared with vehicle/NC-treated CUS mice (P < 0.05 for both), similar 
to the effect of rolipram administration (Durations: P < 0.05; Entries: P > 0.05). In addition, the effects 
of 4DmiR on the durations and entries were not changed in the presence of rolipram.
Effects of 4DmiR on CUS-induced deficits in dendritic complexity and spine density. The 
Golgi staining in Fig.  5 showed the significant decreases of total dendritic length [F(4,15) = 4.591; 
P < 0.01], branching points [F(4,15) = 6.187; P < 0.001] and spine density [F(4,15) = 5.550; P < 0.001] 
in mice subjected to the CUS procedure, compared with the control group. The dendritic complex-
ity and spine density were dramatically affected and showed a significant increase in 4DmiR treated 
mice (P < 0.01 for branching points; P < 0.05 for dendritic length and spine density), compared with the 
CUS group. These effects were similar to those of rolipram administration (P < 0.01 for spine density; 
P < 0.05 for dendritic length and branching points) and were not considerably enhanced in the presence 
of rolipram. These results indicate that long-form PDE4Ds are important in the effects of rolipram revers-
ing CUS-induced decreases of dendritic complexity and spine density.
Effects of 4DmiR on CUS-induced changes in cAMP signaling. As shown in Fig. 6, cAMP con-
centration, PKA activity, and the levels of pCREB and pERK in the PFC were significantly decreased 
by CUS procedure [Fig.  6a–d; FcAMP (4, 14) = 9.045, P < 0.01; FPKA(4, 14) = 5.355, P < 0.01; F pCREB (4, 
14) = 12.32, P < 0.05; F pERK (4, 14) = 8.53, P < 0.05], whereas 4DmiR treatment reversed these altera-
tions and significantly increased cAMP concentration (P < 0.05), PKA activity (P < 0.05), and the levels 
of pCREB and pERK (P < 0.01 for both), similar to the effects of rolipram administration (P < 0.01 for 
pCREB and PKA; P < 0.05 for cAMP and pERK). In addition, the effects of 4DmiR on the regulation of 
cAMP-PKA-CREB and cAMP-ERK1/2-CREB signaling were not substantially changed in the presence of 
rolipram. These results suggest that long-form PDE4Ds are important in the effects of rolipram reversing 
CUS-induced cAMP-PKA-CREB and cAMP-ERK1/2-CREB signaling dysfunction.
Discussion. In the present study, the CUS model of mice successfully copied the depressive-like state 
by reducing the sucrose preference and worsening the coat state, accompanying with the elevation of the 
serum corticorsterone concentration. The animals exposed to the CUS exhibited behavioral deficits in 
tests measuring depression and memory. Furthermore, dendritic retraction and loss of spines, as well as 
down-regulation of cAMP, PKA, pCREB and pERK in the PFC were simultaneously observed in the CUS 
Figure 2. Effects of 4DmiR on CUS-induced changes in neuroendocrine and physical state. (a) CUS 
mice showed a significant increase of serum corticosterone concentration and this effect was reversed by 
4DmiR and/or rolipram treatment. Serum corticosterone concentration was detected using a commercial 
enzyme-linked immunosorbent assay (ELISA) kit. (b) The evaluation of the coat state during each week 
of CUS revealed a significant degradation of the coat state, from week 2 to week 4, in stressed mice in 
comparison to non-stressed mice. Rolipram and/or 4DmiR treatment significantly reversed this effect. 
(c) There was no statistically difference in the body weight, except for week 2. While rolipram alone or 
in combination with 4DmiR significantly disrupted the normal gain in body weight as compared with 
the control starting from week 2. 4DmiR alone did not affect the body weight gain. Values shown are 
means ± SEM; n = 7–10; *P < 0.05, **P < 0.01, ***P < 0.001 compared with non-stressed control (NC + 
Veh); #P < 0.05, ##P < 0.01, ###P < 0.001 compared with CUS (NC + Veh).
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mice. Lentiviral vector-delivered shRNA caused the selective down-regulation of long-form PDE4D4 
and PDE4D5 in the PFC, consistant with previous studies11,20,23. While the other long-form PDE4Ds 
(i.e. PDE4D7, 9) were not examined because of the lack of specific antibodies, but their contributions 
cannot be excluded. The behavioral, cellular and molecular alterations induced by the CUS were atten-
uated or reversed by the long-form PDE4Ds knock-down in the PFC, similar to the PDE4 inhibition 
by rolipram. Moreover, these effects of long-form PDE4Ds knock-down were not affected by chronic 
rolipram treatment. We have previously indicated that locomotor activity of mice was not affected by 
long-form PDE4Ds knock-down in the hippocampus and PFC11,20, suggesting that the observed behav-
ioral differences were not due to potential locomotor activity changes. Together, our data support the 
hypothesis that long-form PDE4Ds, especially PDE4D4 and PDE4D5, are the pivotal variants responsible 
for reverse effects of PDE4 inhibition in the depressive-like symptoms and concomitant memory deficits 
employing the CUS model.
The CUS paradigm is an animal model of depression with good predictive validity (behavioral alter-
ations are reversed by chronic treatment with most current antidepressants), face validity (almost all 
the symptoms of depression are demonstrated), and construct validity (CUS causes anhedonia, the core 
symptom of depression)28. Anhedonia is defined as “the decreased capacity to experience pleasure of 
any sort”29. In an attempt to elucidate the effects of long-form PDE4Ds on the depressed animals, we 
adopted the CUS model in mice. This 4-week design offered a closer resemblance to the chronically 
stressful life events which are the major risk factor for developing depression30. The effectiveness of this 
procedure was monitored by the decrease in the responsiveness to rewards (sucrose preference). It was 
Figure 3. Effects of 4DmiR on CUS-induced changes in antidepressant-like behaviors. (a, b) CUS 
paradigm substantially decreased the sucrose preference of mice and this alteration was reversed by 
4DmiR and/or rolipram treatment. (c, d) Chronically stressed mice displayed significantly increases of 
the immobility time in the FST and the latency to feed in the NSF test compared with non-stressed mice. 
Rolipram and/or 4DmiR treatment significantly reversed these effects. Values shown are means ± SEM; 
n = 7–10; **P < 0.01 compared with non-stressed control (NC + Veh); #P < 0.05, ##P < 0.01 compared with 
CUS (NC + Veh).
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also confirmed by the elevated serum corticosterone, the degradation in the physical coat state, and 
behavioral deficits in the FST and the NSF. These alterations were consistent with previous studies3,28. 
BALB/c mice were used in this experiment for the reason that this strain is more vulnerable to stress 
across a wide range of behavioral tests31,32 and more easy to induce the memory deficits33 than other 
strains of mice after CUS exposure.
Although the sucrose preference was substantially different between the control and CUS groups, 
there existed no statistical difference in the body weights between the two groups at the end of CUS pro-
cedure in the present study. This result is in accordance with some previous studies34, although the weight 
loss is reported in the majority of published studies35. The explanations for this discrepancy may be due 
to the different CUS protocols, species/strains and time points in the different laboratories. Additionally, 
it has been demonstrated that CUS induces a generalized decrease in hedonic responses, whereas weight 
loss is variable across experiments36. Another important evidence supporting the independence of these 
two measures is that chronic antidepressant treatment normalizes the sucrose preference, but not the 
body weights37. Thus, as the validation of successful CUS model, the changes in the sucrose preference 
are more convincing than the changes in body weights. The elevation in serum corticorsterone levels, the 
deterioration of coat state and the behavioral impairments in the FST and the NSF further supported the 
successful experimental protocol of the CUS procedure.
The implications of depression and memory deficits have been revealed by sufficient evidence38. In 
this study, we investigated the effects of long-form PDE4Ds on the impairments of spatial working mem-
ory and object recognition memory in the mouse CUS model of depression. It was found that CUS 
exposure induced memory deficits in BALB/c mice, which is consistent with previous studies33. Stressed 
Figure 4. Effects of 4DmiR on CUS-induced memory deficits. (a) Memory deficits were observed in the 
NOR test in mice submitted to the CUS procedure. The decreased recognition index in the CUS group was 
reverted by 4DmiR and/or rolipram treatment. (b) Escape latency during the acquisition trials (6 trials × 2 
days plus 4 trials × 1 day) in the MWM task in mice. (c, d) Chronically stressed mice displayed significantly 
decrease in durations but not entries in the target quadrant in the probe trial of the MWM task. Rolipram 
and/or 4DmiR treatment significantly reversed these effects. Values shown are means ± SEM; n = 7–10; 
*P < 0.05 compared with non-stressed control (NC + Veh); #P < 0.05, ##P < 0.01 compared with CUS (NC + 
Veh).
www.nature.com/scientificreports/
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Figure 5. Effects of 4DmiR on CUS-induced changes in the dendritic complexity and spine density. (a) 
Representative photomicrograph of Golgi-impregnated cortical pyramidal neurons in the region of infection 
from animals of each group. Scale bar = 50 μ m. (b, c) Summary data showed that the decreases in the total 
dendritic length and the number of branching points induced by CUS were reversed by 4DmiR treatment. 
These effects were similar to those of rolipram administration and were not significantly enhanced in the 
presence of rolipram. (d) Examples of dendrite fragments with visible spines from different groups. Scale 
bar = 10 μ m. (e) The reduction of spine density induced by CUS was rescued by 4DmiR treatment, similar 
to the effect of rolipram administration. And this effect was not significantly enhanced in the presence 
of rolipram. Values shown are means ± SEM; n = 4; **P < 0.01, ***P < 0.001 compared with non-stressed 
control (NC + Veh); #P < 0.05, ##P < 0.01 compared with CUS (NC + Veh).
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BALB/c mice showed a poor learning performance and impaired spatial memory in the MWM, as well 
as impaired object recognition memory in the NOR. Knock-down of long-form PDE4Ds in the PFC, 
a brain region important for mediating cognition associated with depressive disorders39, restored the 
CUS-induced memory deficits in the MWM and the NOR. Furthermore, these effects were not altered in 
the presence of rolipram, indicating a predominant role of long-form PDE4Ds in the reversal of memory 
deficits induced by CUS exposure.
It is well established that loss of neuronal plasticity is involved in the pathophysiology of depression 
and memory deficits14. This study illustrated that CUS exposure contributed to the dendritic retraction, 
simplicity and spine loss in the PFC. The morphological changes were also associated with depressive-like 
behaviors, as well as the impaired spatial memory and object recognition memory. Our findings are in 
accordance with previous studies14,40. We also demonstrated that the disrupted neuronal plasticity in 
the PFC were reversed or prevented by the long-form PDE4Ds knock-down. This effect was not further 
enhanced by the inhibition of the remained PDE4 subtypes and variants by rolipram, supporting the 
important role of long-form PDE4Ds in the counteraction of stress-induced neuronal plasticity disrup-
tion.
CREB is activated by the phosphorylation of its serine 133 (Ser133) region, which is the binding site 
of multiple kinases including cAMP-dependent PKA and mitogen-activated protein kinase (MAPK)41. It 
Figure 6. Effects of 4DmiR on CUS-induced changes in CREB transduction cascade. The prefrontal 
cortical tissues of 3 mm in diameter around the injection site were dissected for cAMP, PKA and western 
blot assays. (a, b) CUS significantly decreased the cAMP concentration and PKA activity in the prefrontal 
cortices, whereas 4DmiR and/or rolipram treatment significantly reversed this effect. (c, d) Western blot 
analysis demonstrated that CUS significantly decreased the protein levels of pCREB and pERK when no 
significant difference was revealed between treatments in the total CREB and ERK levels. Rrolipram and/or 
4DmiR treatment significantly reversed CUS-induced cAMP-PKA-CREB and p44/42MAPK- CREB signaling 
dysfunction. Lower panels are representative cropped immunoblots detected by western blot (full-length 
blots are presented in Supplementary Figure S2) and upper panels are the corresponding quantifications. All 
gels were run under the same experimental conditions and blots were processed in parallel. The boundary 
between the gels was delineated by a black line. The values of densitometric analysis were normalized by the 
level of β-actin. Values shown are means ± SEM; n = 3-4; *P < 0.05, **P < 0.01 compared with non-stressed 
control (NC + Veh); #P < 0.05, ##P < 0.01 compared with CUS (NC + Veh).
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is noted that cAMP-PKA signaling pathway is one of the major signaling transduction mechanisms that 
participate in depression42 and memory deficits43. The ERK1/2 signaling pathway is proposed to be the 
best studied MAPK signaling cascade in depression42. We found that cAMP, PKA, pERK and pCREB 
were all marked reduced response to the CUS procedure in the PFC, which are supported by previous 
studies44,45. The attenuated cAMP-PKA-CREB and cAMP-ERK1/2-CREB signaling pathways underlie 
stress-induced behavioral deficits and neuronal plasticity disruption44, although the contradictory effects 
have also been observed46. However, some CUS models fail to alter ERK1/2 signaling or lead to the 
hyperphosphorylation of ERK1/2 in the PFC47,48. Another contrary finding to those above exist indicates 
that sustained elevation of cAMP signaling causes spine loss in the PFC49. The discrepancy may be due 
to the diversity and complexity of the roles of signaling molecules in stress, as well as the type of stress 
and its duration. The different durations of stress exposure lead to the proper response or the adaptive 
response to CUS paradigm. Here we further demonstrated the reversed expression of these CREB sign-
aling cascade members after stress exposure by the long-form PDE4Ds knock-down. These effects were 
not enhanced in the presence of rolipram, indicating the crucial role of long-form PDE4Ds in the resto-
ration of down-regulated cAMP-PKA-CREB and cAMP-ERK1/2-CREB signaling pathways. Long-form 
PDE4Ds contain an ERK phosphorylation site in the catalytic domain and a PKA phosphorylation site 
in the upstream conserved regions 1 (UCR1), which is distinguished from other variants6. ERK phospho-
rylation transiently inhibits activity of long-form PDE4Ds50,51, followed by a rise in cAMP. The increased 
cAMP causes PKA to phosphorylate UCR1, thereby overcoming its inhibition by pERK51,52. ERK phos-
phorylation acts on PDE4 to regulate cAMP signaling either negatively or positively depending on the 
expression pattern and localization of long-form PDE4s53. Thus, long-form PDE4Ds maybe mediate the 
cross-talk between the cAMP-PKA-CREB and cAMP-ERK1/2-CREB signalling pathways, which is sup-
ported by the findings that PDE4 enzymes orchestrate various signaling cross-talk53.
Taken together, this study provides the first experimental evidence of (i) the alteration of long-form 
PDE4Ds in the PFC of mice subjected to CUS, (ii) the dominant roles of long-form PDE4Ds, especially 
PDE4D4 and PDE4D5, in the reversal of CUS-induced depressive-like behaviors, memory deficits, neu-
ronal plasticity disruption and hypofunction of cAMP-CREB signaling. Thus, our findings could benefit 
the structure- and scaffold-based design of PDE4D variant-selective inhibitors with high therapeutic 
indices for treatment of depression and disorders with memory deficits.
Methods
Animals. Adult male BALB/c mice initially weighing 20–24 g (Vital River Laboratories, Beijing, 
China) were maintained under a 12-h light/ dark cycle at room controlled temperature (22 ± 2 °C) with 
free access to food and water except as mentioned below. All mice were group-housed for 1 week prior to 
the beginning of the experiment and handled daily throughout the experiment to minimize the effects of 
non-specific stress. All experiments were performed in accordance with the National Institute of Health 
Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80–23) and were approved by 
the Animal Care and Use Committees of Beijing Institute of Pharmacology and Toxicology. Efforts were 
made to minimize suffering and to reduce the number of animals used.
Materials. Rolipram was purchased from Sigma-Aldrich (St. Louis, MO, USA). Lentiviral vec-
tors containing the non-targeting negative control (NC) sequence or shRNA sequence in a miRNA 
scaffold targeting long-form PDE4D (4DmiR) were designed using Invitrogen BLOCK-iT Pol 
II miR RNAi expression vector kits and the associated software. The sequence for the PDE4D 
miRNA (shRNA-mir hairpin structure) was 5’-AATGGAGTCACAATCAAGTCAGTTTTGGC- 
CACTGACTGACTGACTTGAGTGACTCCATT-3’. The NC sequence from Invitrogen was 5’-GAA 
ATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCAGTACATTT-
3’. Invitrogen NC sequences were used as the control of PDE4D miRNAs. All the miRNAs and NC 
sequences were cloned into lentiviral transfer vectors and driven by the phosphoglycerate kinase-1 pro-
moter. The vectors contained enhanced green fluorescence protein (EGFP) as a reporter for tracking 
lentivirus-mediated expression as described previously11.
Experimental design. A total fifty mice were randomly distributed into five groups (n = 10): (i) 
NC + vehicle (Veh; 2.5% DMSO) + control (CON); (ii) NC + Veh + CUS; (iii) NC + rolipram (Rol, 
1.25 mg·kg−1) + CUS; (iv) 4DmiR + Veh + CUS; and (v) 4DmiR + Rol + CUS. The dose of rolipram 
was chosen based on our previous studies5,11. After 1 week of acclimatization, mice were provided 5 days 
to establish a stable baseline of sucrose consumption. Then NC or 4DmiR was microinfused into bilateral 
prefrontal cortices of mice. One group was housed in normal conditions (control) and the other groups 
were subjected to CUS. After the 4-week CUS procedure, behavioral performances including the sucrose 
preference test (SPT), the novel object recognition (NOR) test, the novelty suppressed feeding (NSF) test, 
the forced-swim test (FST) and the Morris water-maze (MWM) task were assessed on different days. 
Rolipram or vehicle was administered (i.p.) once a day from the second week and continued up to the 
end, as illustrated in Fig.  7. Given the sedative effects of rolipram at 1.25 mg·kg−1 are absent 1 h after 
administration5,11, training or testing was conducted 1 h after rolipram treatment. After behavioral tests, 
3–4 animals per group were used for biochemical analysis, 4 animals per group for Golgi staining and 
1–2 animals per group for the fluorescence observation of injection sites.
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Mouse surgery and lentiviral microinfusions. Mice were weighed and anesthetized with ketamine 
(100 mg/kg, i.p.) and xylazine (20 mg/kg, i.p.) before placed in a stereotaxic apparatus (Stoelting, Wood 
Dale, IL, USA). All the surgical supplies were sterilized before the operation. The bilateral prefrontal 
cortices infusions were performed via a 10 μ l Hamilton microsyringe with a 30-gauge needle fitted to 
the arm of the stereotaxic apparatus. An incision was made in the scalp and a hole was drilled in the 
skull over the injection site, following the coordinates54: the bilateral prefrontal cortices: anterior–poste-
rior (AP, from Bregma) + 1.5 mm, medial–lateral (ML, from midline) ± 0.5 mm, and dorsal–ventral (DV, 
from dura) − 1.2 mm from dura. The 30-gauge-needle was lowered into the dorsal limb of the prefrontal 
cortex (PFC). Lentiviral vectors containing NC or 4DmiR (4 × 106 TU/μ l, 1 μ l/side) were infused at a rate 
of 0.2 μ l/min using a UMP3 microsyringe injector and Micro4 controller (World Precision Instruments, 
Sarasota, FL, USA). The needle was slowly retracted after additional 5 min in order to assure adequate 
diffusion of the vectors.
Chronic unpredictable stress procedure. Chronic unpredictable stress regimen was modified from 
that previously described in mice55. Mice were subjected to different kinds of stressors for four con-
secutive weeks: (1) cold swimming (10 °C); (2) cage tilting (45°); (3) restraint stress; (4) overhanging; 
(5) foot shock (0.8 mA, 5-s duration, 60-s inter-shock interval); (6) white noise (110 dB); (7) tail pinch 
(1 cm apart from the end of the tail); (8) damp sawdust (200 ml water absorbed in sawdust bedding); 
(9) sawdust-free cage; (10) sawdust-free cage with 200 ml water (21 °C); (11) continuous cage shaking 
(high speed horizontal shaking); (12) overnight illumination and (13) water or food deprivation. Two or 
three stressors were applied daily: once in the morning (beginning at 0900 hours), once in the afternoon 
(beginning at 1400 hours), and overnight. The stress procedure in the first two weeks was presented in 
Table  1 and repeated in an unpredicted manner during the following two weeks. Control mice were 
housed in a separate room, having no contact with the stressed mice.
Serum corticosterone levels. Serum corticosterone concentration was determined using commer-
cially available corticosterone enzyme immnuoassay kits (Enzo Life Sciences, Farmingdale, NY, USA) 
according to the manufacturer's instructions. Following behavioral testing, mice were sacrificed by 
decapitation. Blood samples were collected and allowed to clot. Serum samples were separated by cen-
trifugation (3000 rpm, 15 min) at 4 °C and stored at − 20 °C until time of assay. Considering the circadian 
rhythm56, mice were bled between 10:00 and 12:00 h for measurement of corticosterone levels.
Coat state and body weight. To define the dynamics of the CUS response, the coat state and the 
body weight of each animal were evaluated weekly57. The coat-state evaluation by observers unaware of 
treatments involved the assessment of five different body parts: dorsal coat, ventral coat, tail, forepaws 
and hind paws (head and neck were not included for the reason of surgery). For each body part, a score 
of 0 was given for a well-groomed coat and 1 for an unkempt (dirty, piloerection, greasy, fluffy or less 
dense) coat. The final score was obtained by adding the scores for each body part and dividing by the 
Figure 7. Experimental design. Mice were provided 5 days to establish a stable baseline of sucrose 
consumption following the 1-week acclimatization. After lentiviral vectors harbouring the NC or 4DmiR 
sequence were microinfused into bilateral prefrontal cortices, mice were housed in normal conditions 
(control) or subjected to the chronic unpredictable stress (CUS) procedure for 28 days. Behavioural 
experiments including the sucrose preference test (SPT), the novel object recognition (NOR) test, the novelty 
suppressed feeding (NSF) test, the forced-swim test (FST) and the Morris water-maze (MWM) test were 
performed after the CUS procedure. Rolipram (1.25 mg/kg) or its vehicle (saline containing 2.5% DMSO) 
was injected (i.p.) once daily, beginning from 6 h after the viral infusions (day 5) and continuing until d47 
when the animals were sacrificed (SAC) for biochemical assays.
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total number of body parts. The final score has been pharmacologically validated as an index of the 
general physical state of BALB/c mice.
Behavioral procedures. Sucrose Preference Test (SPT). Mice were subjected to the sucrose prefer-
ence test before (baseline measurement) and after the application of chronic stress procedure. A 5-day 
sucrose preference protocol was conducted as previously described58,59. Briefly, mice were individually 
housed and habituated to two identical bottles filled with tap water (water/water) on days 1 and 2 or 1% 
sucrose solution (sucrose/sucrose) on days 3 and 4. On day 5, mice were given a free choice between 
two bottles for 10 h, one with 1% sucrose solution and another with tap water. To minimize the effect of 
side preference, the position of the bottles was switched in the middle of the test (5 h). To prevent the 
spillage of liquids resulting from temperature difference, bottles were filled in advance and the temper-
atures between the room and the drinking solutions were balanced. No food and water deprivation was 
applied before the test. Sucrose preference was calculated as sucrose consumed/(sucrose consumed + 
water consumed) × 100%.
Novelty-Suppressed Feeding (NSF) Test. The NSF test was performed during a 5-min period as described 
previously5. In brief, mice were deprived from food for 24 h and then were individually placed in a corner 
of the white plexiglas chamber (54 × 28 × 21 cm) for 5 min. The floor was covered with 2 cm of sawdust. 
Four pellets of food (regular chow) were placed in the center of the floor. The latency to eat (defined 
as the mouse chewing or biting the pellet with the forepaws, but not merely sniffing or toying with the 
pellet) the food was recorded.
Forced-Swim Test (FST). The test was performed in mice as described previously60,61. Briefly, mice were 
gently introduced into a glass cylinders (20 cm diameter, 45 cm height) filled with water (23 ± 1 °C; depth 
28 cm) for 6 min. Immobility time (the time during which mice floated motionlessly only with the small 




1 cold swimming (6 min, in 10 °C water) sawdust-free cage (8–12 h) overnight illumination
2 restraint stress (1 h) damp sawdust (8–12 h ) _
3
electric footshock (0.8 mA, 
5-s duration, 60-s inter-
shock interval for 1 h)
45° cage tilting (8–12 h ) food deprivation (overnight)
4 tail pinch (1 cm apart from the end of the tail, 1 min)
sawdust-free cage with 
200 ml water (21 °C, 8 
− 12 h )
_
5 overhanging (30 min) 45° cage tilting (8–12 h ) _
6 white noise (1 h) restraint stress (1 h) _
7 sawdust-free cage (8 -12 h) cold swimming (6 min, in 10 °C water) water deprivation (overnight)
8 continuous cage shaking (1 h)
sawdust-free cage with 
200 ml water (21 °C, 8 
− 12 h )
_
9 restraint stress (1 h) 45° cage tilting (8 − 12 h ) _
10
electric footshock (0.8 mA, 
5-s duration, 60-s inter-
shock interval for 1 h)
overhanging (30 min) overnight illumination
11 damp sawdust (8 − 12 h )
tail pinch (1 cm apart 
from the end of the tail, 
1 min)
_
12 continuous cage shaking (1 h) restraint stress (1 h) food deprivation (overnight)
13 overhanging (30 min) cold swimming (6 min, in 10 °C water) _
14 white noise (1 h)
sawdust-free cage with 
200 ml water (21 °C, 8 
− 12 h )
overnight illumination
Table 1.  Chronic Unpredictable Stress Procedure.
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Novel Object Recognition (NOR) Test. The NOR test was carried out as previously described11. 
Experiments were conducted in a dimly lit room. During the habituation session, mice were allowed to 
become familiar with the testing box for 5 min. Twenty-four hours later, mice were again placed in the 
same apparatus and were individually exposed to two identical objects placed in two corners of the box 
for 5 min (the sample session). After another 24-h interval, mice were returned to the box with a previ-
ously presented familiar object and a novel one for 5 min (the test session). Exploration was defined as 
initiatively facing, sniffing or touching the object (within 2 cm from the object). The accumulative time 
exploring each object (Tf and Tn for familiar and novel objects, respectively) was recorded for determi-
nation of the recognition index [RI = Tn/(Tn + Tf)].
Morris Water-Maze (MWM) Task. The MWM task was performed following the procedures described 
in earlier studies11,62. Behavioral testing was conducted in a circular pool (100 cm diameter, 35 cm depth), 
which was divided into four equally spaced quadrants. The pool was filled to the depth of 17 cm with 
water (21 ± 1 °C) made opaque by addition of powdered milk. A circular platform was placed in the 
center of one of the quadrants 1.5 cm below the surface of the water. The pool was located in a well-lit 
room with some external cues, which remained in the same location throughout the acquisition and the 
probe trials. Mice were individually placed in the pool facing the wall at different starting points, except 
for the target quadrant containing the hidden platform. Animals were trained to escape by swimming 
and climbing onto the platform during the acquisition trials (6 trials ×  2 days plus 4 trials × 1 day; 16 
trials in total). Those failed to find the hidden platform within 90 s were guided towards it and stayed 
there for 30 s before being removed. The latency to escape by swimming onto the platform was recorded. 
Twenty-four hours after the last acquisition training trial, the probe trial was conducted in the absence 
of the platform. The number of entries and the time spent in the target quadrant were recorded with 
the cut-off time 60 s.
Golgi impregnation and dendrite analysis. FD Rapid GolgiStai kit (FD NeuroTechnologies, 
Ellicott City, MD, USA) was used for Golgi impregnation of tissue. Golgi staining was performed accord-
ing to manufacturer’s instructions. In brief, blocks were impregnated into solutions A and B for 2 weeks 
at room temperature in the dark. Seventy-two hours after placing in solution C (4 °C, in the dark), 
coronal cryostat sections (100 μ m) were cut from the PFC (±0.25 mm from the coronal section through 
the injection site in rostro-caudal direction, a total of four to five sections per animal) on a freezing 
microtome (Leica, Wetzlar, Germany) and mounted onto gelatinized slides. Following drying in the dark, 
sections were rehydrated, reacted in solutions D and E, and dehydrated with 50, 75, 95, and 100% etha-
nol, respectively. Finally, sections were cleared in xylene and coverslipped with resinous mounting media.
For quantitative analysis, five to six neurons from each animal and four animals per group were 
analyzed. The criteria used to select neurons for reconstruction have been fully described previously63. 
Briefly, neurons chosen for analysis had to be well impregnated, clearly distinguishable from adjacent 
cells or precipitant, located in the region of infection and have continuous unbroken dendrites. Neurons 
were digitally reconstructed, traced using Image-Pro Plus software, Version 7.0 (Media Cybernetics, 
Bethesda, MD, USA). The total dendritic length and the number of branching points were measured 
by Sholl analysis64. Spines were counted at high magnification (100 × oil objective). Only branches over 
20 μ m in length were included in the study. Spine density was calculated per 10 μ m of dendritic length.
Western-blot analysis. Western blotting was performed as described previously65 with minor modi-
fications. Punched prefrontal cortical tissues (3 mm in diameter around the injection site on both sides) 
were extracted by RIPA lysis buffer (Millipore, Billerica, MA, USA) plus protease inhibitor and phos-
phatase inhibitor cocktail (Thermo Pierce, Rockford, IL, USA). Fifty microgram of total protein was 
resolved by electrophoresis, transferred onto nitrocellulose membranes and blocked by 5% skimmed 
milk solution. The membranes were incubated with rabbit antibody against PDE4D3, PDE4D4, PDE4D5 
(all at a dilution of 1:500; FabGennix, Frisco, TX, USA), cAMP response element-binding (CREB) pro-
tein, pCREB (both at a dilution of 1:500; Millipore, Billerica, MA, USA) or β -actin (at a dilution of 
1:3000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4 °C overnight. After washing and incubating 
with secondary antibodies (at a dilution of 1:3000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
the specific bands were detected and quantified using Gel-Pro Analyzer software, Version 3.1 (Media 
Cybernetics, Bethesda, MD, USA).
cAMP assay. The lance cAMP kit (PerkinElmer, Waltham, MA, USA) was used to determine intracel-
lular cAMP concentrations of the lysed samples. The assays were performed following the manufacturer’s 
instruction in 384-well format. Counts at 665 nm obtained in cAMP standard curves allowed the quan-
titative determination of the cAMP concentration in samples. The signal at 615 nm is useful to identify 
dispensing or quenching problems. All experiments were performed in the presence of 0.05% bovine 
serum albumin and 0.5 mM isobutyl-methyl-xanthine to allow accumulation of cAMP.
Protein kinase A (PKA) activity assay. PKA activity was determined using a non-radioactive pro-
tein kinase assay kit (Enzo Life Sciences, Farmingdale, NY, USA) according to the manufacturer’s rec-
ommendations. Lysed samples were added to the appropriate wells according to ELISA protocol and 
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the purified active PKA included with the kit was used as the positive control. The assay was developed 
with tetramethylbenzidine substrate and the color development was stopped with acid stop solution. The 
intensity of the color was measured at 450 nm in a microplate reader. The results were presented as the 
percentage of PKA activity in each group to that in the control group.
Statistical analysis. The data are expressed as means ± standard error (SEM) and analyzed with the 
statistical analysis software GraphPad Prism, Version 5.0 (GraphPad, San Diego, CA, USA). All data 
were analyzed using one-way analysis of variance (ANOVA) except for the data from the acquisition 
training of the water maze, coat state and body weight, which were analyzed using two-way ANOVA. 
Bonferroni’s tests were used for post hoc multiple treatment comparisons. Statistical significance was 
considered when P < 0.05.
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